~~<i id='FF22791C05'><strike id='FF22791C05'><tt id='FF22791C05'><pre id='FF22791C05'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

fashion

author：explore 2025-09-06 02:11:12 - browse：7894

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Flu, Covid vaccination rates decline, new survey data show

focus

knowledge

hotspot

focus

knowledge

HealthsecretaryXavierBecerrareceivesanupdatedCovid-19boosterinSeptember.DrewAngerer/GettyImagesWASHI

WSS

What will Novo Nordisk's VC do with its influx of cash?

IVG is promising — but it won’t replace IVF quite yet

What will Novo Nordisk's VC do with its influx of cash?

Intarcia’s device

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

CRISPR base editing slashes cholesterol levels in monkeys

explore

fashion

focus

Cancer drug shortages should be causing more outrage

FDA panel to weigh approval of NurOwn, controversial ALS drug

Hepatitis C has a cure — but many Americans still lack access to it

What we owe ALS patients — and why one company fell short

Trump demands the U.S. pay no more for drugs than other countries … again

FDA panel to weigh approval of NurOwn, controversial ALS drug

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA panel to weigh approval of NurOwn, controversial ALS drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The biotech scorecard for Q4: 16 stock

focus

Biotech stock slump in 2023: awaiting the turnaround

Setback for rare diseases as Taysha Gene Therapies pulls back

Medical student insurance fails on mental health care coverage

Stop Congress from blocking public access to science

Biotech stock slump in 2023: awaiting the turnaround

Will an HIV vaccine ever be a reality?

knowledge

hotspot

focus

knowledge